Kevin Paul Foley

This inventor holds 32 USPTO granted patents and 24 published patent applications and 1 EPO patent, primarily in Cancer Therapy. Top assignee: Synta Pharmaceuticals Corporation. Active years: 2009-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kevin Paul Foley. Retrieved from https://idiyas.com/inventor/kevin-paul-foley

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 32 (Patent Applications = 24)

% Patents Active = 65.6

EPO Patents = 1 (Patent Applications = 6)

Average Co-Inventor Count = 4.1

ph-index = 16

Forward Citations = 579(Granted Patents)

Location History:

Waltham, MA (US) (2009 - 2015)
Cambridge, MA (US) (2010 - 2015)
Landsdale, PA (US) (2014 - 2015)

Company Filing History:

32 out of 162

Synta Pharmaceuticals Corporation

patents

Years Active: 2009-2015

Loading Chart...

Areas of Expertise:

Hsp90 Inhibitors

Cancer Therapy

Triazole Compounds

Pyrazole Compounds

Imidazole Compounds

Proliferative Disorders

B-raf Associated Cancer

Non-Hodgkin's Lymphoma

HSP90 Activity Modulation

Triazone Compounds

Compounds for Treatment

c-Met Mutations

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9206162 - Triazole compounds that modulate Hsp90 activity (2015-12-08),

2. 9205086 - Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor (2015-12-08),

3. 9156794 - Imidazole compounds that modulate HSP90 activity (2015-10-13),

4. 9108933 - Method for treating proliferative disorders associated with mutations in c-Met (2015-08-18),

5. 9101614 - Method for treating non-Hodgkin's lymphoma (2015-08-11),

6. 9090603 - Compounds for the treatment of proliferative disorders (2015-07-28),

7. 9090569 - Triazone compounds that modulate HSP90 activity (2015-07-28),

8. 9006277 - Triazole compounds that modulate HSP90 activity (2015-04-14),

9. 8969396 - Method for treating a B-raf associated cancer with an Hsp90 inhibitor (2015-03-03),

10. 8927548 - Triazole compounds that modulate HSP90 activity (2015-01-06),

11. 8921407 - Pyrazole compounds that modulate HSP90 activity (2014-12-30),

12. 8901308 - Triazole compounds that modulate Hsp90 activity (2014-12-02),

13. 8835464 - Triazole compounds that modulate HSP90 activity (2014-09-16),

14. 8648104 - Method for treating proliferative disorders associated with mutations in c-Met (2014-02-11),

15. 8629285 - Imidazole compounds that modulate HSP90 activity (2014-01-14),

Title: Innovations in Cancer Therapy by Kevin Paul Foley

Introduction

Kevin Paul Foley, an accomplished inventor based in Waltham, MA, has made significant contributions to the field of oncology through his patents. With a total of 32 patents to his name, he has consistently demonstrated a commitment to advancing cancer treatment methods.

Latest Patents

Foley’s latest innovations include groundbreaking work on cancer therapy using a combination of Hsp90 inhibitory compounds and an EGFR inhibitor. This patent outlines a pharmaceutical combination that includes these inhibitors, providing a method for treating proliferative disorders in patients. Additionally, he developed triazole compounds that modulate Hsp90 activity, which are crucial for preventing or treating hyperproliferative disorders like cancer.

Career Highlights

Currently, Foley is associated with Synta Pharmaceuticals Corporation, a key player in the development of new cancer therapies. His extensive work in the pharmaceutical industry has positioned him as a leading inventor in the quest for effective cancer treatments.

Collaborations

In his journey, Foley has collaborated with esteemed colleagues such as Zhenjian Du and Weiwen Ying. These partnerships have undoubtedly contributed to the innovative breakthroughs that Foley has achieved in his research and patent applications.

Conclusion

Kevin Paul Foley continues to be a pivotal figure in the development of novel cancer therapies through his inventive spirit and collaborative efforts. His dedication to innovation is reflected in his numerous patents aimed at improving treatment options for patients facing hyperproliferative disorders.

Profile summary based on public USPTO records.